Infectious Diseases (except HIV/AIDS)
Showing page 182 of 716 pages of list content
-
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial
This article's authors -
Home Care Follow up determine the point of inversion of IL-6 levels in relation to C-Reactive Protein as the cytokine storm marker in COVID-19
This article's authors -
Determinants of passive antibody efficacy in SARS-CoV-2 infection
This article's authors -
Long-term symptoms after SARS-CoV-2 infection in a cohort of hospital employees: duration and predictive factors
This article's authors -
Immunogenic superiority and safety of Biological E CORBEVAX vaccine compared to COVISHIELD (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial
This article's authors -
Where the truth really lies: Listening to voices from African American communities in the Southern States about COVID-19 vaccine information and communication
This article's authors -
Evaluation of the Panbio™ COVID-19 Antigen Rapid Diagnostic Test in subjects infected with Omicron using different specimens
This article's authors -
Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020-2021
This article's authors -
Multi-organ impairment and Long COVID: a 1-year prospective, longitudinal cohort study
This article's authors -
15-month follow-up of anti-spike receptor binding domain (RBD) SARS-CoV-2 antibodies among healthcare workers in Boston, MA
This article's authors